Subscribe
shutterstock_1124671937_jhvephoto
JHVEPhoto / Shutterstock.com
2 August 2019AmericasSarah Morgan

Bausch Health resolves IP litigation with Teva

Canadian pharmaceutical company  Bausch Health and generics maker  Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Bausch targets India-based firm over IBS drug generic
20 June 2023   Pharma giant claims infringement of two patents | Hyderabad-based rival’s letter offering details of proposed generic allegedly lacked certain required details.
Big Pharma
Bausch settles $300m antitrust case over diabetes drug price hikes
13 September 2021   Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.
Americas
US judge dismisses attorney’s ‘opportunistic’ whistleblower suit
14 May 2020   A Californian judge has thrown out an attorney’s whistleblower lawsuit alleging Bausch Health Companies fraudulently obtained a patent for its ulcerative colitis drug Apriso.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
Bausch targets India-based firm over IBS drug generic
20 June 2023   Pharma giant claims infringement of two patents | Hyderabad-based rival’s letter offering details of proposed generic allegedly lacked certain required details.
Big Pharma
Bausch settles $300m antitrust case over diabetes drug price hikes
13 September 2021   Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.
Americas
US judge dismisses attorney’s ‘opportunistic’ whistleblower suit
14 May 2020   A Californian judge has thrown out an attorney’s whistleblower lawsuit alleging Bausch Health Companies fraudulently obtained a patent for its ulcerative colitis drug Apriso.

More on this story

Big Pharma
Bausch targets India-based firm over IBS drug generic
20 June 2023   Pharma giant claims infringement of two patents | Hyderabad-based rival’s letter offering details of proposed generic allegedly lacked certain required details.
Big Pharma
Bausch settles $300m antitrust case over diabetes drug price hikes
13 September 2021   Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.
Americas
US judge dismisses attorney’s ‘opportunistic’ whistleblower suit
14 May 2020   A Californian judge has thrown out an attorney’s whistleblower lawsuit alleging Bausch Health Companies fraudulently obtained a patent for its ulcerative colitis drug Apriso.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler